INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Lucid Cap Mkts

INmune Bio (NASDAQ:INMB) was upgraded by equities researchers at Lucid Cap Mkts from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.00.

INmune Bio Stock Performance

Shares of NASDAQ:INMB opened at $1.33 on Wednesday. The company has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $1.72. INmune Bio has a one year low of $1.16 and a one year high of $11.64. The stock has a market capitalization of $35.35 million, a price-to-earnings ratio of -0.63 and a beta of 0.77.

Institutional Trading of INmune Bio

Several hedge funds have recently made changes to their positions in INMB. XTX Topco Ltd raised its holdings in INmune Bio by 240.9% during the second quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after purchasing an additional 88,928 shares in the last quarter. Westside Investment Management Inc. boosted its holdings in INmune Bio by 384.0% in the 3rd quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after purchasing an additional 82,075 shares in the last quarter. JPMorgan Chase & Co. increased its position in INmune Bio by 1,042.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after purchasing an additional 66,700 shares during the period. State Street Corp increased its position in INmune Bio by 22.3% during the 4th quarter. State Street Corp now owns 347,259 shares of the company’s stock worth $542,000 after purchasing an additional 63,426 shares during the period. Finally, Jain Global LLC purchased a new position in shares of INmune Bio during the 4th quarter worth approximately $66,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.